mHealth Israel_Japan MedTech & Digital Health: Go-To-Market Overview

05 3 1
• ( )
•
•
• &
Please use this Zoom Q&A button!

0 80 . ,0 1 0 1 2 8
2 10 1 2 A 0 0
0 1
A 1 8A 02 0 2 2 A
88 1 0 2 1 2 A 1A 0
2 10 0 2 1 2 , 1

0 80 . ,0 1 0 1 2 8
W 8 H 2 I F F JD L JHO 1 ( L O H J LJ H P
W 8 J I ML J F JD L JHOL J L
7HMJ T JHF L 4 LJP H 0 L 3 HMJ J 7L L L H 6JH M L H P
6 JF ML 1 M LJPS
U9 L T M J F H P
, , ,
,
( (
( ( ,
( ,
( ,
, ( (
(
,( ( (
(
( ,(
( ( ,
,
(
(
( ,
( ,
(
(
(
( , (
5L J F
. H L LPI F
8 J I ML LPI F

0 80 . ,0 1 0 1 2 8
J A31 6 B 21 4 31 4 3 1 B A ( 2 $(I
J 3 C B 1 1 1A B A 3 4 1 AB 1 B A 16B B 0 .
J , 1 1A AC3 1A 1 A 1 1 4 B A 3B 4
J , B 1 4 21 1 B B A B 6 1 1 A 1B 4 3
Source From BMI Research “Worldwide Medical Devices Market Forecasts to 2021” (MIZUHO Bank)
Trends in the Global Medical Device Market Regional average growth rate of medial equipment market
Market Size of Medical Device by country 2016
0
500
1,000
1,500
2,000
2,500
3,000
3,500
4,000
4,500
2012 2013 2014 2015 2016 2017e 2018e 2019e 2020e 2021e
$100
million
North America Latin America Japan
China Other Asia Central & East Europe
Middle East & Africa Western Europe
1,459
281 245 188 132 97 86 67 58 48
0
200
400
600
800
1,000
1,200
1,400
1,600
1,800
U
.S.
Japan
G
erm
an
C
hina
France
England
Itary
C
anada
Korea
Austrelia
$100million
G9 M G9 E GEL
%& % &
6EG N C GA 9
49 A C GA 9 - %
39 9 ( %
0 A 9 .
7 G A9 )
0 G9 19 1JGE ) .
5 A 19 GA 9 %
8 G 1JGE (
2 E 9

.8. 0 1 15 5 . 1, 2 . 1,. . .25 . ,
$
5 5
& 9SMR SR 9SMR SR - )
0GGS (
( 1F J (
) 64 ) .
C HS ) ,
BNJQJR ) )
, 5 J JRNY ( -
- JI SRNH (
. ( (
& 1JH SR 3NHONR SR -
&& MNPNT
& 6FQG S
&( CS MNGF & .
&) 1 1 FYR & -
& 1S SR BHNJR NKNH & -
& 1 N SP J B YNGG & -
&, 4F QFR SIFO &
&- P QTY & )
&. BQN M JTMJ & (
6YNIFR & (
& 2 A 1F I &
0LNPJR &
( F HSRN JINHFP B JQ & &
) B 9YIJ JINHFP &
B OJ &
&.., , &,
BSY HJ 338 QJI CST & JINHFP 3JZNHJ 2SQTFRNJ SK &, J H FIJ G 900 4
$
5 5
& 9SMR SR 9SMR SR & ,
64 &,
( BNJQJR &)
) JI SRNH & (
1F J &
MNPNT && (
, 2SZNINJR .
- 0GGS - )
. 2F INRFP 7JFP M - &
& B OJ )
&& 3FRFMJ (
& 1JH SR 3NHONR SR
&( 1S SR BHNJR NKNH (
&) 1 1 FYR )
& 4 NPS ( .
& B 9YIJ JINHFP ( -
&, SZF N ( )
&- ( ( )
&. ENQQJ (
CJ YQS -
& P QTY -
BQN M JTMJ
( 7S TN F
) CS MNGF
6J NRLJ (
$
5 5
& JI SRNH .
9SMR SR 9SMR SR
( 5 J JRNY & ,
) 64 &- -
MNPNT &, &
BNJQJR &
, 2F INRFP 7JFP M &)
- 0GGS & (
. B OJ & &
& 1JH SR 3NHONR SR & &
&& 1F J & )
& 1S SR BHNJR NKNH - -
&( 4 NPS -
&) ENQQJ 1NSQJ , -
& SZF N .
& ( ,
&, P QTY
&- CJ YQS ) .
&. BQN M JTMJ ) ,
2FRSR ( .
& 34 CB D B8A ( .
6J NRLJ ( ,
( 4I F I NKJ HNJRHJ ( (
) 7SPSLNH ( &
8R YN NZJ BY LNHFP (
Tyco Fresenius B Braun Smith & Nephew 1998
Abbott Siemens 1999
$ 2 5
9FTFRJ J HSQTFRNJ F J N MNR ST NR J Q SK FPJ
(

0 80 . ,0 1 0 1 2 8
, E 7 7 DE 6D D 7FDEC D E E C E C E 6 E E DD
E 6 CE E E
M. C E 2 C . 7 6 . C E C 7 . 7 6 . C E IN
2 FC6 ( 6E , C E 1 D E D D ( D E , E C E ( E E )0 . C6

0 80 . ,0 1 0 1 2 8
M , C6 I E C 6E 6 7 E E G DD .6 6 D FDEC D E C6 FE 7D D 6
N 6C E 6C 76 6C E C 76 6C E JO
FC7 ( 7E C 6E 2 D E D .6 6 D ( 6 D E E C 6E 6 ( E E 0 )1 6C7

0 80 . ,0 1 0 1 2 8
. A E D E A A E D H E
n . A E D : D A : D .
• E : D A C AE D A A D E D
C III I C A E
n . A E D : ) A D A A E D .)
• A E D H C A CC D E D
C III C A E
n . A E D : ) A D C D E A A A
.)
• E D E D
C III J C A
n , C A & A : D . E D A ( H C A &.)(
• ( E CC D
CE III C A
n / D E A . ( H E & A /.(&
• E : D A D H I : D E H E D A D H A E
CE III C C A E

.8. 0 1 91 . 1, 2 . 1,. . .2 . 9 ,
2AE AE F E AE E CF D E AE D A C A C : FE D A C A C
FDF AFE C E
E CAN :K F E CF D E AE D A C A C F AEA M
6 F A FD E A K F FD : A F A C AD C D E AFE
1 :CA FE - AC ) A FE, BF F 7K D K F D 0 E F 3 AF EA A M 7 FFC F A AE
.K F A C , * ) :ACCAFE M E 5KD: F FEE C, FK CM ( F KCC AD FEE C
5> >I .D I R CJL 7 AF > M >L E >IA 0 P J H I .710
LFH 7FIFM L
M JIMF CJL SD I L>
JJLAFI> FJIT
, JH I 7FIFM LM
)
F FJI R I
2FM > R >L
OAD >HJOI M CJL
H AF > A PF M (
F FJI R I F FJI R I
7FIFM L JC 1AO > FJI
O OL JL M F I
>IA < EIJ JDR
M JIMF CJL S >MF
L M >L ET
7FIFM L JC 3 > E
6> JOL >IA C>L
M JIMF CJL S FIF >
L M >L ET
7FIFM L JC 1 JIJHR
<L>A >IA 4IAOM LR
M JIMF CJL S L> F >
FH H I > FJIT
8P LPF JC E 5> >I .D I R CJL 7 AF > M >L E >IA 0 P J H I .710

0 80 . ,0 1 0 1 2 8
1F 3 J I3 A D 5 D
1F J 3DD DE3 5
4 ED DJDE
A E 5 D 3 DJDE D
53 D H E E 3AA 53E 4 E
E 5 J
) 3 C /D
E C D C / C C C C
I 4 D5 A 4 ED D C
C C 38
1 3 E E 3E E D C
3 - C 38 E D C
C
E 5 3 E DDF
3 3 D
5 A E H E E 5FEE
E 5 J 3 3 F 35EF
C 3 E 3 C 3
8 C C 3 38 C C3
8 C 3 C C C C
1JDE E 5 3E 3 D DF5 3D 4
DD D 3 4 D A FA 5 D C8 (
C C 38
1JDE E 5 3E D 3 E DDF DF5
3D 53 35 H3 C8 3 8 C C
C 38
/ 3 J 3D
E 3E E
3 3 J 5 J F5
A3E E D A JD 53 4F
38 C CD C 3
C8 D C E 3D
3 C8 C C8 E 3D
C C C C3
, A 5 D 3 3E E 3AJ F A E
C 38 C E C C
D 3 C E C D
5 J DFAA E DJDE A3
E F 5E C8 C 38 C 3 C
E 3 3C E C
3 DE 5 3
- A E 53 5 5J 4J
3 J 3 D D IE D 3 E J
IA 5E3 5J
. -) 8 8 D 3C 3
3D C3
3 DE 5 5 D 53 5 E3DE3D D C
C 3C 3 3 3 D
3 C 3D C 3 C C
3 DE 5 5 D 53 5 C8 DC
D 3 A 5 DD E 5 J E
5 D5 A
, 3 E 53
3 53 D EE 3
3 D 5 EJ
23 3 3 E3 .3A3 D DE
D DF5 3D M H D 3 H E
D3
, 38 C C C C C
E 3
53E F A E A35 3
E3 53 C 3 I 8C
E E 3
3 D D DFAA E DJDE C8 3 C
D C 3
C 38
2 5 J A E A EJ D
53 5 FDE J

0 80 . ,0 1 0 1 2 8
, , , , , ,
, ,
Development of the most advanced medical devices in the world
Collaboration between industry, academia, and the government, and promotion of
cutting-edge diagnostic and treatment system development
(Development of Medical Devices and Systems for Advanced Medical Services: budget amount for fiscal year 2017
- 4.38billion yen)
Formulation of evaluation indices and development guidelines that allow smooth development and reviews
Development of medical devices through collaboration between medicine and
industry
Facilitate collaboration between corporations, universities, and other parties
possessing manufacturing technology, with medical institutions,
to develop and implement devices that can answer the needs of medical sites
(Development of Medical Devices through Collaboration between Medicine and Industry: budget amount for
fiscal year 2017 - 3.45 billion yen)
Market cultivation,
planning of designs and
concepts
Development, clinical trials,
manufacturing, provision of
services
Sales,
marketing
Support by the Network for Supporting Development of Medical Devices
Provide continuous support according to development stages in the form of “accompanying consultation”
Comprehensively mobilize development institutions and provide one-stop support
such as for discovering medical site needs and for industrialization
(approval and authorization, intellectual properties, market cultivation, finances).

0 80 . ,0 1 0 1 2 8
- 3 2 A2
n 0 A 2 3 A2
• ( H 3 2 A2
• A 3 2 A A 2 2 2 A
• 2 2 A % A A
• A 2 2 A2 A 2A 2 2 23 A 2 3
A2
n / 3 A
• A 3 A A A 2
% A
A 3 2 2 A
A 2 A A
2 2 2 3 2 A
• / 3 A A 3 ) 1
• / 3 A A A A 2A

0 80 . ,0 1 0 1 2 8
The 1st Well Aging Society Summit Asia-Japan Preliminary
In Japan, there is strong demand and opportunity for transformation in our healthcare
ecosystem.
Our rapid aging population is driving strong social demand for change. Japan has some of the
most advanced basic sciences, applied sciences such as regenerative medicine, and has
quality healthcare data from 120 million people. This provides opportunity for new technology,
new business models, new culture to be implemented through partnerships within and globally.
FOCUS TOPIC
The technology; Biotech startups
The business model; Quality digital health
The culture; Well aging society
(elderly care and support, preventive healthcare)
l Format: Partnering event (symposium, pitch) inviting diverse global players such as
healthcare ventures, investors and sponsors (Pharma, Medical device, IT, trading companies,
insurers, VCs etc) and local governments from Japan
l Date: October 10-12, 2018
co-event with “Bio-Japan”, Asia's No.1 partnering event for the global biotechnology industry
l Venue: Yokohama, Japan
l Supported by
AMED(Japan Agency for Medical Research and Development),
WEF (World Economic Forum) …in consideration,
Government of Japan (Cabinet Office, Ministry of Economy, Trade and Industry(METI),
Ministry of Health, Labour and Welfare)
l For more information contact:
Healthcare Industries Division, METI healthcare-events@meti.go.jp, +81-3-3501-1790

0 80 . ,0 1 0 1 2 8
/
n & / / /
n / / /
/ / /

Japanese Organization for Medical Device Development, Inc.

6 .8. 0 1 1 . 1, 2 . 1,. . .2 6 . ,
asano@jomdd.com
Shotaro Asano
Business Development Director
Japanese Organization for Medical Device Development
(JOMDD)
Focuses on digital heath, medical device development.
Based in Tokyo, Japan.
Previously a corporate venture capital VP at Recruit
Strategic Partners, inc.
Organizer of this webinar and mHealth.JP

1 8 08 . 8
• . 8 2 8,
+ experts with various back grounds
CEO, Takahiro Uchida, M.D., Ph.D., M.Sc, GMP.,
- Medical Director at Boston Scientific Corporation
- Medical Officer/Reviewer at FDA
- Harvard SPH (2002), MBA(2010)
Chief Business Officer, Taiki Ishikura
- Board Member at P5, Inc. / Marketing Manager at M3, Inc.
- Co-founder of Aqumen Biopharmaceutical
- Stanford MBA
- Takeda Ventures, Inc
- Stanford Medicine X Innovation Sourcing Team / Biodesign Program
Chief Operating Officer, In Guto
- Marketing Producer at M3 ,Inc.
- Product Manager at Livesense
- Hustler in IT business development
U.S. COO, Heita Ueshima
- Sales & Marketing Manager at JSR
- marketing, channel management, PMI, business
development for IVD and biologics products

0 D B F 2E B CB CE 1 9 8 , I 8 , I CDA B /B8
(
• /B8 B A 9 8 BBCI CB ECA 0 D B
• ) IJ B M D E C BBCI CB
– CEJ ) EF .,) 1,) A E 8
– B 8 , I CDA B
– / F B FF E J
– . B9E F B
– F 1 E B
Idea
Tech
Research
StartUp
Revenue
Globalize
M&A
IPO
16 pipelines
8 invested
8 built in-house

. . 80 1 1 8 . 1, . 1,. . . . ,
• . . . 1 2. 8.
• . 8. 8 1 1 0
Genomic Horizontal No need No need
No need No need
Robotics Prosthesis
Telemedicine Horizontal
Digital Therapy Diabetes
Brain/Neuro Alzheimer’s
AI Japanese NLP
Image Recog. Digital Pathology
(Blood Cancer)
Pain Fibromyalgia
fund
raising!
fund
raising!
fund
raising!

0 80 . ,0 1 0 1 2 8
& & &
Academia / Med School Deal Source
Government / Prefectures Deal Source
Association Deal Source U.S + Global Network
• Exposed to 250+ deals/seeds per year

D . . 2 2 , . . 3 21 0. 2 02 2 2 2 0
• . 2 .82 . 8 .
– /. 0 . 82 3.0
– 2 . . 2 21 0. 2. 0. 2
21 20 . 1 . 2. . 82
– 2 1 . . 2 2 . 2. . 82

4.8. 0 41 1 4 . 1, 2 . 1,. . .2 .4 4,
, ,
Population
Hospitals
Medical Doctors
Nurses (registered)
Pharmacists
127M
8,442
319,480
(0.25%)
1,634,119
(1.29%)
301,323
(0.24%)
325.7M
5,534
713,800
(0.22%)
2,857,180
(0.88%)
312,500
(0.09%)
Data source:
http://www.mhlw.go.jp/toukei/saikin/hw/ishi/16/dl/kekka_1.pdf
http://www.mhlw.go.jp/toukei/saikin/hw/ishi/16/dl/kekka_3.pdf
https://www.nurse.or.jp/home/statistics/pdf/toukei01.pdf
https://www.bls.gov/ooh/healthcare/physicians-and-surgeons.htm
https://www.bls.gov/oes/current/oes291141.htm
https://www.bls.gov/ooh/healthcare/pharmacists.htm

.8. 0 1 15 5 . 1, 2 . 1,. . .25 . ,
Age 75
Age 70
Age 6
(before schooling)
10% self-pay
20% self-pay
30% self-pay
20% self-pay
30%
self-pay
Active worker with
high income
Non-worker or
with low income
For who turned 70 after 2014

6 .8. 0 1 1 . 1, 2 . 1,. . .2 6 . ,
1119.1
908.5
576.6
284.7
96.2
88.4
82.7
81.9
81.7
71.6
Japanese Red Cross Society
National Hospital Organization
Social Welfare Organization
Saiseikai Imperial Gift Foundation
Tokushukai Medical Group
Seirei Social Welfare Community
JA Nagano Koseiren
Nose Kids Clinic
JA Niigata Koseiren
JA Hokkaido Koseiren
Osaka Prefectural Hospital Organization
Revenue 2012
Chart created by Shotaro Asano
Data Source: Tokyo Shoko Research
Billion Yen

.8. 70 1 1 7 . 1, 2 . 1,. . .2 . ,
10
1732.1
1311.7
1195.5
955.1
539.1
491.8
424.0
411.6
343.0
338.9
312.3
208.1
168.8
214.3
112.5
85.0
64.7
80.8
53.8
59.9
Takeda Pharmaceutical Company
Astellas Pharma
Otsuka Holdings
Daiichi Sankyo Company
Eisai
Chugai Pharmaceutical
Mitsubishi Tanabe Pharma Corporation
Sumitomo Dainippon Pharma
Kyowa Hakko Kirin
Shionogi
Revenue FY2016 R&D FY2016
http://answers.ten-navi.com/pharmanews/9919/
Billion Yen

N - D : : 0F M H C CF .: 8 :J 8: :J: CDA: H , 8
• . : CFH FCI CD: CJ H C 8 I
: D:8 : 8 C H:
CH :H H H : H 8 I H C
• 0H I C H 1FCH :I DDFCJ:
• 2:8: H : . H I : 1 FA D FH :F
H H 8 I , CF FI :J: CDA: H

.8. 0 1 91 . 1, 2 . 1,. . .2 . 9 ,
https://www.yakuji.co.jp/entry58247.html
3063.9
2552.8
2127.0
1231.0
MEDIPAL HOLDINGS CORPORATION
Alfresa Corporation
SUZUKEN
Toho Holdings
Revenue FY2016
Billion Yen

J . 1A C 8 A 0 E E C
%
• 0 A : 0 2 , E C
,3 C ACD H 2 C8 A I
: A

.8. 0 1 1 . 1, 2 . 1,. . .2 3. ,
5,236.0
5,041.8
4,468.7
3,458.8
2,866.3
Nippon Life Insurance Company Nissei
Japan Post Insurance
Dai-ichi Life Holdings
Sumitomo Life Insurance Company
Meiji Yasuda Life Insurance Company
Revenue FY2016
https://www.fsa.go.jp/news/29/hoken/20170602-1/01.pdf
Billion Yen

H -2 2 A 1 82 : 2 : : 2 D: D ,
• 0:AA : 1 : :23 A D : 8 2
: , ,0
• 2: : : .: 2 2 2 2
• 2 1 : 8 : 2 0 1 : AC
8 2 A

.8. 0 1 1 . 1, 2 . 1,. . .2 3. ,
https://www.jetro.go.jp/ext_images/en/mjcompany/directory/Japan_medical.pdf

N 0 D 3F M H C :CF 1 8 , J , J CDA H
%
• 4 H 232 1 8 I F 8 C
• 5 I F 8 1 85 . FH
• 0 D H ADCFH 1 8 , J C:
H A F H
Data Source: MHLW 2014
Japan Medical Device
Domestic/Import

, ,5 81,52 , 2 5 0 8 .2 ,3 2 3 5 5
Data Source: Nikkei
Billion Yen
408.5
162.7
105.8
57.8
52.5
SHIP Healthcare Holdings
Medias Holdings
Kawanishi Holdings
Win Partners
YAMASHITA MEDICAL INSTRUMENTS
Revenue FY2016

0 0 60 E0 , 3 20 C 2 C 2
• , 6 0 8 1D 02 6
3 1 6 2 0 D 20 3 .,

,7, 81, 2 , 2 0 8 .2 ,3 2 3 7
0 ) ( 0 0 1 (
1489.9
188.0
81.5
48.5
37.9
34.0
16.6
14.3
M3
SMS
Medical Data Vision
EMS tems
MTI
Kanamic Network
MEDICAL SYSTEM NETWORK
MRT
Market Cap March2018
Data Source: Nikkei
Billion Yen

.8. 0 1 1 . 1, 2 . 1,. . .2 3. ,

T 1 I 5JA C LCH HJ 3 C E - NC - N EHI L 0
• 9 E B ELB
– 3 P IJH M L HML C HLB JH L JLMI
L JIJC
– 7 C MJ L IHEC P B AC A C
• . IEHP ELB JNC
– J N LCN IIJH B JHM ,BJH C L E B ELB
– 0 MJ H I C J I C EEP LCN
• -CACL E LB J I MLC
– ,EC C E LJC E L JL P ,MJ II MJJ LEP J C IIJHO 3 8-
• 0
– 3 P ICEHL JHM R0 A J HA CLCH S
– 8L JLMI JHM R LMJ E 2 AM A JH C AS
• EH D B C
– 0,5 B EE A P R 3S 1 I L JLMI

2?2 , 4 D @ 21 0 2 02 2 2 2 @ 0
• . 8 ?@2 4
• 2?@ ?
? 11 0

Copyright © 2018 M3, Inc. All rights reserved.
Using the Internet to enable as many people
as possible to live happier,
healthier lives, and reduce, as much as
possible, unnecessary medical costs
Introduction of M3 group
28 March 2018

Copyright © 2018 M3, Inc. All rights reserved. 42
M3 Group Overview
M3, Inc.
Headquarters: Tokyo, Japan
Founded: 2000
Listed: TSE1 (code 2413)
Shareholders: Sony 34%
Group Employees: 5,100
Market Value: $ 14 billion
M3 Group Registered Doctor Members:
4,000,000+ Globally
Medicine
Media
Metamorphosis

Business Platform
m3 PLATFORMS
4.0+ Million Physician Members Globally
Hospitals,
Pharmacies &
Clinics
CUSTOMERS
Pharmaceutical
Companies
Consumers &
Others
SERVICES
Career Placement
Clinic M&A Advisory
e-Medical Records
e-Appointments
e-Promotion
e-Clinical Trial
e-Marketing Research
eCSO
AskDoctor.com
Product Rating
Services

GLOBAL Portal Sites
Medigate, Korea
80% of Korean MDs
M3 USA
80% of U.S. MDs
Doctors.net.uk, UK
90% of U.K. MDs
King Yee, China
2.0+ Million Chinese MDs
4+ MILLION members globally
ViDAL, France,
Germany, Spain
330,000 EU MDs
Health Impetus, India
100,000 Indian MDs
M3, Inc. Japan
80% of Japanese MDs

Japan (m3.com)
U.S.A (MDLinx)
U.K. (Doctors.net.uk)
Other Nations
(M3 Global Research,
MDLinx, Russia)
Korea (Medigate)
(thousand)
China (Medlive)
FY08 09 10 11 12 13 14 15 16 17
Q3
Number of Physician Members and Panelists (Global)
India
France, Germany, Spain
(VidalGroup)
0
500
1,000
1,500
2,000
2,500
3,000
3,500
4,000
4,500
4+ million
members worldwide
Over 4 million physicians utilize M3’s global platforms

New Service Development in the
Medical Internet Sector
Internet-Powered PE Style Business
Expansion in Healthcare Industry
(2000~2010) (2011~)
Approach Internet Internet + Real Operations
Service
Coverage
Web-based
eTools Entire Value-Chain
Potential Business
Domains ~10 30 ~ 50
(~ 200 including overseas)
Profitability
High profitability
(Mid absolute profit)
High absolute profit
(Mid profitability)
Small Medium ~ Large
M3 is uniquely positioned to transform the health care industry via its 1) Platform
2) Industry Expertise and
3) Human Resources (management and engineering)
Strategy Change in Business Development

“Making use of the Internet to increase, as much as
possible, the number of people who can live longer and
healthier lives, and to reduce as much as possible, the
amount of unnecessary medical costs.”
~ 2010
2011 ~
Evolution via MR-kun for pharmaceutical
e-Marketing - Engine #1
Evolution via Mr. Finder for pharmaceutical e-
R&D - Engine #2
Power of Mr. Finder in Drug Development
Plus

Other SMOs
M3.com doctors exceeded by number and speed in collecting cases
versus other SMOs for a particular Endocrinology and Metabolism trial
Numberofpatientenrollment
0
100
200
300
400
500
600
700
800
900
1,000
1,100
1,200
1,300
1,400
1,500
A B C D E F G H I J K Lm3.com
Case study
Expedited enrollment of cases compared to other SMOs
Patient Enrollment in Large-Scale Trials

Evolution of M3 Growth Drivers
Main Initiatives
Full-scale entry into the field of Advanced Medicine, as the third
growth driver for M3
Added Value
Creation
2000 2010 2020
¾ Seeds Rocket / M3i
¾ Various solutions within
cancer specialties
¾ M3 AI Labo
¾ Genome Diagnosis / G-TAC
¾ e-Clinical Trials
¾ M3 Career (Job placement for
physicians)
¾ MR-kun Family
¾ Web Surveys

Businesses Supported by the Advanced Medicine Platform
Continued fortification and commonization of the M3 platform.
Objective to expand the advanced medicine business to equal or
greater scale than existing businesses such as “MR-kun Family”
and “Clinical Trials”
Clinical
Trial
Execution
Market
Channel
Expansion
Business
Administration
Enhancement
Web
Marketing
Marketability
Evaluation
Regulatory
Strategy
Tama Bio COSMOTEC βα
Organic M&A
Advanced Medicine Platform
S u p p o r t S u p p o r t S u p p o r t S u p p o r t S u p p o r t
M&A
JAMECS

M3’s A.I. Initiatives within Healthcare
Highly expert
team
consisting 10+
members such
as A.I.
engineers and
data scientists
¾ Analysis of user activity logs across M3
operated sites such as m3.com
¾ Application of A.I. to optimally customize user
experiences created an uplift of a couple billion
yen in profit
¾ Established internal team dedicated to A.I.
medical device regulations
¾ Including induction of overseas technologies,
results already seen in several diagnostic
imaging areas, with product development
(approval) in progress
¾ Provision of M3 resources to support companies
researching frontline A.I. medical technologies
¾ Large scale partnerships in review
Accuracy of Diagnosis for Disease X
Personalized Content Delivery
94%
95%
Sensitivity
Specificity
LPixel βα
A.I. Support Platform
Support Support Support
Website Activation
A.I. Diagnostics
Incubation

Advanced Medical Device Platform: COSMOTEC
Business Expansion Outside of Cardiac
Surgery Field
Coverage of Cardiovascular
Surgical Sites
¾ Approx. 1,000 transactions with medical institutions annually.
Track record of transaction with 98% (approx. 500 sites) of institutions conducting
cardiovascular surgery
¾ Top class in domestic market share of major devices for cardiac surgery
¾ Focus also on seed excavation and in-house development. Expanded share of
total sales to 25% over the past 10 years for non cardiac surgery devices
Share of sales contributed by non
cardiac surgery devices
0%→ 25%(approx.) in 10 yrs
Vascular Surgery / Cancer / Reproductive Medicine
New Product Induction + Development
98.0%
2.0%Uncovered sites:
Covered Sites:

Sales Operating Profit & Net Profit
(mn yen) (mn yen)
* Extraordinary profit from acquisition of MPI: 1,034 mn yen
00
(6m)
01 02 03 04 05 06 07 08 09 10 11 12 13 14 15 16 17
FCT
Annual Results & Forecast for FY2017
Operating Profit
Net Profit
107 480 8911,5632,2763,8545,7297,4758,534
11,811
14,646
19,040
26,007
36,759
51,346
64,660
78,143
90,000
00
(6m)
01 02 03 04 05 06 07 08 09 10 11 12 13 14 15 16 17
FCT
13,738
8,878
-93
46
255 509 895
1,683
2,677
3,597 3,990
4,803
6,031
7,648
9,294
12,704*
16,061
20,022
25,050
29,000
-93
62 136 279 493 991 1,609 1,965 2,363 1,938
3,486
4,492
5,5987,844*
10,428
13,493
16,938
19,500

mHealth Israel_Japan MedTech & Digital Health: Go-To-Market Overview

Recommandé

Recommandé

Contenu connexe

Similaire à mHealth Israel_Japan MedTech & Digital Health: Go-To-Market Overview

Similaire à mHealth Israel_Japan MedTech & Digital Health: Go-To-Market Overview (20)

Plus de Levi Shapiro

Plus de Levi Shapiro (20)

Dernier

Dernier (20)

mHealth Israel_Japan MedTech & Digital Health: Go-To-Market Overview